A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral CGM097, a p53/HDM2-interaction Inhibitor, in Adult Patients With Selected Advanced Solid Tumors

Trial Profile

A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral CGM097, a p53/HDM2-interaction Inhibitor, in Adult Patients With Selected Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs CGM 097 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Novartis
  • Most Recent Events

    • 11 Oct 2016 Data from this trial was used to develop PK/PD models of thrombocytopenia and the cytokine Growth Differentiation Factor 15 and a kinetic (K)/PD model of tumor size outcomes presented at the 41st European Society for Medical Oncology Congress
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
    • 28 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top